hexahydro-cyclopenta[b]furan | 32923-08-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢呋喃
• 英文名称: hexahydro-cyclopenta[b]furan
• 英文别名: Oxabicyclo(3,3,0)octan；3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]furan
• CAS: 32923-08-3
• 化学式: C₇H₁₂O
• 分子量: 112.172
• InChiKey: QHINYJQPBCMLCJ-UHFFFAOYSA-N

物化性质

• 熔点：
  -100 °C
• 沸点：
  143-144 °C
• 密度：
  0.983±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢碘酸 作用下， 生成 hexahydro-cyclopenta[b]furan
  参考文献：
  名称：

  Hueckel; Gelmroth, Justus Liebigs Annalen der Chemie, 1934, vol. 514, p. 233,245

  摘要：

  DOI：

文献信息

• [EN] POLYCYCLIC EPOXIDES AND COMPOSITIONS THEREOF WITH ANTI-CANCER ACTIVITIES<br/>[FR] ÉPOXYDES POLYCYCLIQUES ET COMPOSITIONS À BASE DE CEUXS-CI PRÉSENTANT DES ACTIVITÉS ANTICANCÉREUSES
  申请人：VERSITECH LTD

  公开号：WO2016181312A1

  公开（公告）日：2016-11-17

  The present technology provides polycyclic epoxides of Formula I, compositions comprising such expoxides and methods of using such epoxides. In particular, these compounds are useful for inhibiting cancer cell proliferation and tumor angiogenesis or treating ovarian, breast, prostate, liver, pancreatic, and colon cancers, as well as leukemia.

  目前的技术提供了化学式I的多环氧化物，包括含有这种环氧化物的组合物以及使用这种环氧化物的方法。具体来说，这些化合物对抑制癌细胞增殖和肿瘤血管生成或治疗卵巢癌、乳腺癌、前列腺癌、肝癌、胰腺癌和结肠癌等方面是有用的。
• OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20150344489A1

  公开（公告）日：2015-12-03

  The present invention relates to novel substituted oxindole derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising compounds I and their use for the treatment of vasopressin-related disorders.

  本发明涉及公式I的新型取代氧吲哚衍生物，其中变量如权利要求和描述中所定义。该发明还涉及包含化合物I的药物组合物，以及它们用于治疗与加压素相关的疾病。
• VLA-4 INHIBITOR
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1757602A1

  公开（公告）日：2007-02-28

  An object of the present invention is to provide a compound which selectively inhibits binding of a ligand and α4β1 integrin (VLA-4), a process for producing the compound, and a medicament containing the compound. A compound represented by the formula (I) etc. orasaltthereof, a process for producing the compound or a salt thereof, a medicament containing the compound or a salt thereof, as well as a preventive and/or a therapeutic agent for a disease caused by cell adhesion, for example, inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease and rejection reaction at transplantation, containing the compound or a salt thereof as a primary component. [wherein Y1 represents a divalent aryl group etc. , V1 represents an aryl group etc., and R11 to R14 represent H, OH or a halogen atom etc.]

  本发明的一个目的是提供一种化合物，该化合物选择性地抑制配体与α4β1整合素（VLA-4）的结合，以及包含该化合物的药物的制备过程。化合物的结构如公式（I）所示，或其盐，制备该化合物或其盐的过程，包含该化合物或其盐的药物，以及作为细胞粘附引起的疾病（例如炎症反应、自身免疫疾病、癌症转移、支气管哮喘、鼻阻塞、糖尿病、关节炎、银屑病、多发性硬化症、炎症性肠病和移植排斥反应等）的预防和/或治疗剂，包含该化合物或其盐作为主要成分。【其中Y1代表双价芳基等，V1代表芳基等，R11至R14代表H、OH或卤素原子等】
• HIV PROTEASE INHIBITORS AND METHODS FOR USING
  申请人：Ghosh Arun K.

  公开号：US20110118330A1

  公开（公告）日：2011-05-19

  Compounds that inhibit proteolytic enzymes of Human Immunodeficiency Virus (HIV) are described. Preparation of the inhibitors, pharmaceutical compositions containing them, and uses of the compounds or compositions for the treatment of HIV infections are also described.

  描述了抑制人类免疫缺陷病毒（HIV）蛋白酶酶的化合物。还描述了抑制剂的制备、含有它们的药物组合物、以及这些化合物或组合物用于治疗HIV感染的用途。
• INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY
  申请人：SHIONOGI & CO., LTD

  公开号：US20150203450A1

  公开（公告）日：2015-07-23

  Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: or its pharmaceutically acceptable salt, wherein Y is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocyclyl; T is —CR 7 ═ or —N═; U is —CR 8 ═ or —N═; R 2 is hydrogen, halogen, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted acyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, or substituted or unsubstituted alkyloxycarbonyl; R 3 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, or the like; and R 4 , R 7 and R 8 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, or the like.

  本申请公开了一种作为AMPK激活剂有用的化合物。一种由以下结构表示的化合物或其药学上可接受的盐，其中Y被取代或未取代的烷基，取代或未取代的烯基，取代或未取代的炔基，取代或未取代的芳基，取代或未取代的杂环芳基，取代或未取代的环烷基，取代或未取代的环烯基，或取代或未取代的杂环烷基；T为—CR7═或—N═；U为—CR8═或—N═；R2为氢，卤素，氰基，硝基，羧基，取代或未取代的烷基，取代或未取代的烯基，取代或未取代的酰基，取代或未取代的氨基甲酰基，取代或未取代的烷基硫基，取代或未取代的烷基亚砜基，取代或未取代的烷基砜基，或取代或未取代的烷氧羰基；R3为卤素，取代或未取代的烷基，取代或未取代的烯基，取代或未取代的炔基，取代或未取代的芳基，取代或未取代的杂环芳基，取代或未取代的环烷基，取代或未取代的环烯基，取代或未取代的杂环烷基，或类似物；且R4、R7和R8分别独立地为氢，卤素，羟基，氰基，硝基，羧基，取代或未取代的烷基，取代或未取代的烯基，取代或未取代的炔基，取代或未取代的芳基，取代或未取代的杂环芳基，取代或未取代的环烷基，取代或未取代的环烯基，取代或未取代的杂环烷基，或类似物。